The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

Table 1

The prognostic value of the IGFBP1 mRNA expression in ovarian cancer.

	Overall survival			Progression-free survival
	Cases	HR (95% CI)	value	Cases	HR (95% CI)	value
Histology
All cancer patients	1656	0.74 (0.64−0.86)	0.00012	1435	0.71 (0.62−0.83)	6.2e−06
Serous cancer patients	1207	0.86 (0.72−1.03)	0.099	1104	0.91 (0.77−1.07)	0.24
Endometrioid cancer patients	37	2.66 (0.3−23.76)	0.36	51	0.21 (0.05−0.91)	0.021
Pathological grades
I	56	0.44 (0.17−1.16)	0.09	37	0.33 (0.09−1.23)	0.084
II	324	0.76 (0.56−1.03)	0.08	256	0.87 (0.62−1.22)	0.42
III	1015	0.89 (0.74−1.08)	0.24	837	0.88 (0.73−1.07)	0.19
Clinical stages
I and II	135	0.42 (0.17−1.04)	0.052	163	0.41 (0.19−0.87)	0.016
III and IV	1220	0.86 (0.74−1.01)	0.063	1081	1.11 (0.96−1.29)	0.15
Chemotherapy
Contains platin	1409	0.79 (0.67−0.93)	0.005	1259	0.79 (0.69−0.91)	0.00094
Contains taxol	793	0.85 (0.68−1.05)	0.13	715	1.16 (0.96−1.41)	0.13
Contains taxol+platin	776	0.82 (0.65−1.02)	0.077	698	1.16 (0.95−1.41)	0.15

.